{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T08:03:57Z","timestamp":1747469037956},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1694","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved the injectable interleukin (IL)-17A\/17F antagonist bimekizumab-bkzx (Bimzelx \u2013 UCB) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy. Bimekizumab is the first IL-17A\/17F antagonist to be approved in the US. It was approved in the European Union for the same indication in 2021.<\/jats:p>","DOI":"10.58347\/tml.2024.1694b","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T18:22:40Z","timestamp":1704824560000},"page":"11-13","source":"Crossref","is-referenced-by-count":1,"title":["Bimekizumab (Bimzelx) for Psoriasis"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,1,22]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T18:22:41Z","timestamp":1704824561000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1694b"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":0,"journal-issue":{"issue":"1694","published-online":{"date-parts":[[2024,1,22]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1694b","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]}}}